Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Non-Current Assets (2016 - 2025)

Viking Therapeutics' Non-Current Assets history spans 12 years, with the latest figure at $131000.0 for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 88.14% year-over-year to $131000.0; the TTM value through Dec 2025 reached $2.6 million, down 42.98%, while the annual FY2025 figure was $131000.0, 88.14% down from the prior year.
  • Non-Current Assets for Q4 2025 was $131000.0 at Viking Therapeutics, down from $712000.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $1.7 million in Q1 2022 and bottomed at $131000.0 in Q4 2025.
  • The 5-year median for Non-Current Assets is $1.1 million (2024), against an average of $992400.0.
  • The largest annual shift saw Non-Current Assets surged 1011.19% in 2022 before it crashed 88.14% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $134000.0 in 2021, then soared by 1011.19% to $1.5 million in 2022, then fell by 15.04% to $1.3 million in 2023, then dropped by 12.65% to $1.1 million in 2024, then plummeted by 88.14% to $131000.0 in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Non-Current Assets are $131000.0 (Q4 2025), $712000.0 (Q3 2025), and $834000.0 (Q2 2025).